PT - JOURNAL ARTICLE AU - Ali S. Omrani AU - Muna A. Almaslamani AU - Joanne Daghfal AU - Rand A. Alattar AU - Mohamed Elgara AU - Shahd H. Shaar AU - Tawheeda B. H. Ibrahim AU - Ahmed Zaqout AU - Dana Bakdach AU - Abdelrauof M. Akkari AU - Anas Baiou AU - Bassem Alhariri AU - Reem Elajez AU - Ahmed A. M. Husain AU - Mohamed N. Badawi AU - Fatma Ben Abid AU - Sulieman Abu Jarir AU - Shiema Abdalla AU - Anvar Kaleeckal AU - Kris Choda AU - Venkateswara R. Chinta AU - Mohamed A. Sherbash AU - Khalil Al-Ismail AU - Mohammed Abukhattab AU - Ali Ait Hssain AU - Peter V. Coyle AU - Roberto Bertollini AU - Michael P. Frenneaux AU - Abdullatif Al Khal AU - Hanan M. Al kuwari TI - The First Consecutive 5000 Patients with COVID-19 in Qatar; a Nation-wide Cohort Study AID - 10.1101/2020.07.15.20154690 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.15.20154690 4099 - http://medrxiv.org/content/early/2020/07/16/2020.07.15.20154690.1.short 4100 - http://medrxiv.org/content/early/2020/07/16/2020.07.15.20154690.1.full AB - Background There are limited data on Coronavirus Disease 2019 (COVID-19) outcomes at a national level, and none after 60 days of follow up. The aim of this study was to describe national, 60-day all-cause mortality associated with COVID-19, and to identify risk factors associated with admission to an intensive care unit (ICU).Methods This was a retrospective cohort study including the first consecutive 5000 patients with COVID-19 in Qatar who completed 60 days of follow up by June 17, 2020. Outcomes included all-cause mortality at 60 days after COVID-19 diagnosis, and risk factors for admission to ICU.Results Included patients were diagnosed with COVID-19 between February 28 and April 17, 2020. The majority (4436, 88.7%) were males and the median age was 35 years [interquartile range (IQR) 28– 43]. By 60 days after COVID-19 diagnosis, 14 patients (0.28%) had died, 10 (0.2%) were still in hospital, and two (0.04%) were still in ICU. Fatal COVID-19 cases had a median age of 59.5 years (IQR 55.8–68), and were mostly males (13, 92.9%). All included pregnant women (26, 0.5%), children (131, 2.6%), and healthcare workers (135, 2.7%) were alive and not hospitalized at the end of follow up.A total of 1424 patients (28.5%) required hospitalization, out of which 108 (7.6%) were admitted to ICU. Most frequent co-morbidities in hospitalized adults were diabetes (23.2%), and hypertension (20.7%). Multivariable logistic regression showed that older age [adjusted odds ratio (aOR) 1.041, 95% confidence interval (CI) 1.022–1.061 per year increase; P <0.001], male sex (aOR 4.375, 95% CI 1.964–9.744; P <0.001), diabetes (aOR 1.698, 95% CI 1.050–2.746; P 0.031), chronic kidney disease (aOR 3.590, 95% CI 1.596–8.079, P 0.002), and higher BMI (aOR 1.067, 95% CI 1.027–1.108 per unit increase; P 0.001), were all independently associated with increased risk of ICU admission.Conclusions In a relatively younger national cohort with a low co-morbidity burden, COVID-19 was associated with low all-cause mortality. Independent risk factors for ICU admission included older age, male sex, higher BMI, and co-existing diabetes or chronic kidney disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was requiredAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Hamad Medical Corporation Institutional Review Board (MRC0120191).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and analyzed during the current study are available from the corresponding author on reasonable request.